Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Susan, Bakke"'
Autor:
Tito Fojo, Susan E. Bates, Olaf Van Tellingen, Frank Balis, Barry Goldspiel, Andrew Dwyer, Rob Robey, Susan Bakke, Ann Rutt, Clara Chen, Richard Wilson, Maureen Edgerly, Jame Abraham
Purpose: P-glycoprotein (Pgp) antagonists have had unpredictable pharmacokinetic interactions requiring reductions of chemotherapy. We report a phase I study using tariquidar (XR9576), a potent Pgp antagonist, in combination with vinorelbine.Experime
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d530611d13c96f5fb5d2ab30697e39e
https://doi.org/10.1158/1078-0432.c.6517044
https://doi.org/10.1158/1078-0432.c.6517044
Autor:
Tito Fojo, Susan E. Bates, Olaf Van Tellingen, Frank Balis, Barry Goldspiel, Andrew Dwyer, Rob Robey, Susan Bakke, Ann Rutt, Clara Chen, Richard Wilson, Maureen Edgerly, Jame Abraham
Supplementary Data from A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9bc5dd34120db4e3f442f113f307915
https://doi.org/10.1158/1078-0432.22439604
https://doi.org/10.1158/1078-0432.22439604
Autor:
Rob Robey, Richard H. Wilson, Susan E. Bates, Andrew J. Dwyer, Clara C. Chen, Ann Rutt, Frank M. Balis, Jame Abraham, Tito Fojo, Barry R. Goldspiel, Olaf Van Tellingen, Maureen Edgerly, Susan Bakke
Publikováno v:
Clin Cancer Res
Purpose: P-glycoprotein (Pgp) antagonists have had unpredictable pharmacokinetic interactions requiring reductions of chemotherapy. We report a phase I study using tariquidar (XR9576), a potent Pgp antagonist, in combination with vinorelbine. Experim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b8098eebe68daa7cc4fcbff66216205
https://doi.org/10.1158/1078-0432.ccr-08-0938
https://doi.org/10.1158/1078-0432.ccr-08-0938
Autor:
Louis Davis, Frank M. Balis, Bharat Damle, Susan Bates, Manish Agrawal, Jame Abraham, Ann Rutt, Brigitte C. Widemann, Herb Kotz, Susan Bakke, Daryl S. Sonnichsen, Tito Fojo, Maureen Edgerly, David Lebwohl
Publikováno v:
Journal of Clinical Oncology. 21:1866-1873
Purpose: The epothilones are a novel class of nontaxane microtubule-stabilizing agents. BMS-247550 is a semisynthetic analog of the natural product epothilone B. We conducted a phase I study administering BMS-247550 as a 1-hour intravenous infusion d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d9e4685cca8c86ad09d03002e77951b
https://doi.org/10.1200/jco.2003.03.063
https://doi.org/10.1200/jco.2003.03.063
Autor:
Peter L. Choyke, Beverly Meadows, Raymond C. Bergan, Barry R. Goldspiel, Clara C. Chen, Robert W. Robey, Tito Fojo, Thomas M. Smith, Isagani Chico, Susan Bakke, Susan E. Bates, Maria J. Merino, William D. Figg, Min H. Kang
Publikováno v:
Cancer. 92:1577-1590
BACKGROUND PSC 833 is a second-generation P-glycoprotein (Pgp) antagonist developed to reverse multidrug resistance (MDR). The authors conducted a Phase I study of orally administered PSC 833 in combination with vinblastine administered as a 5-day co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::360c2c64686b0bf79965b66f3e05d927
https://doi.org/10.1002/1097-0142(20010915)92:6<1577::aid-cncr1484>3.0.co
https://doi.org/10.1002/1097-0142(20010915)92:6<1577::aid-cncr1484>3.0.co
Autor:
Ira S. Ockene, Yunsheng Ma, Mihaela C Blendea, Barbara Handschin, Qin Liu, Susan Bakke, Emily Panza, Kristin L. Schneider, Sherry L. Pagoto
BACKGROUND: The comorbidity of type 2 diabetes mellitus (T2DM) and depression is associated with poor glycemic control. Exercise has been shown to improve mood and glycemic control, but individuals with comorbid T2DM and depression are disproportiona
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8b80626c2328180ddf1bdd5eb1544df
https://europepmc.org/articles/PMC3134367/
https://europepmc.org/articles/PMC3134367/
Autor:
R N Ann Rutt, Manish Agrawal, R N Maureen Edgerly, Paul Thambi, Sen H. Zhuang, Tito Fojo, Frank M. Balis, R N Susan Bakke, Susan Bates, Herb Kotz
Publikováno v:
Cancer. 103(9)
BACKGROUND The epothilones are a novel class of microtubule-stabilizing agents. Ixabepilone (BMS-247550; NSC 710428) is a semisynthetic analog of the natural product epothilone B. The authors conducted a Phase I study by administering ixabepilone to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4300b9a652170c4ae727fb8445d7fa5
https://pubmed.ncbi.nlm.nih.gov/15800893
https://pubmed.ncbi.nlm.nih.gov/15800893
Autor:
Rob Robey, Peter Choyke, R N Beverly Meadows, David Bartlett, David Schrump, M.P.H. Elizabeth Hung M.S., Richard Alexander, Seth M. Steinberg, Maria Merino, Tito Fojo, Jame Abraham, Susan Bates, R N Susan Bakke, R N Ann Rutt
Publikováno v:
Cancer. 94(9)
BACKGROUND Adrenocortical carcinoma (ACC) is rare, nearly always fatal, and to the authors' knowledge has few nonsurgical treatment options. Based on in vitro studies demonstrating the efficacy of mitotane as a P-glycoprotein (Pgp) antagonist, and ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0d8720d2dbeacb5f64c4b6c3b3ac8e4
https://pubmed.ncbi.nlm.nih.gov/12015757
https://pubmed.ncbi.nlm.nih.gov/12015757
Autor:
Victor, Sandor, Susan, Bakke, Robert W, Robey, Min H, Kang, Mikhail V, Blagosklonny, Jonathon, Bender, Rebecca, Brooks, Richard L, Piekarz, Eben, Tucker, William D, Figg, Kenneth K, Chan, Barry, Goldspiel, Antonio Tito, Fojo, Stanley P, Balcerzak, Susan E, Bates
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 8(3)
The primary objectives of this trial were to define the maximum tolerated dose (MTD) and to characterize the toxicities and pharmacokinetics of depsipeptide (FR901228) given on a day-1 and day-5 schedule every 21 days. A secondary objective of the tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2502edaa2da47ce5fe7ab228c01b2111
https://pubmed.ncbi.nlm.nih.gov/25979924
https://pubmed.ncbi.nlm.nih.gov/25979924
Autor:
Laila Dahmoush, Richard Piekarz, Douglas M. Kingma, Rosemary M. Altemus, Rob Robey, Susan Bakke, Victor Sandor, Maria L. Turner, Susan E. Bates, Wyndham H. Wilson
Publikováno v:
Blood. 98(9)
Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::578efe1defadd57b115bc1918a73e9e0
https://pubmed.ncbi.nlm.nih.gov/11675364
https://pubmed.ncbi.nlm.nih.gov/11675364